Author  
Place of duty  
Title   진행성 위선암 환자에서 Etoposide , Doxorubicin , Cisplatin ( EAP ) 복합 화학요법의 효과 ( Etoposide , Doxorubicin , Cisplatin ( EAP ) Combination Chemotherapy for Advanced Gastric Cancer )
Publicationinfo   1992 Jan; 024(04): 562-570.
Key_word   Etoposide, Adriamyein, Cisplatin, Stomach cancer
Full-Text  
Abstract   Recently, Etoposide, Adriamycin and Cisplatin(EAP) combination chemotherapy is widely used in patients with advanced gastric cancer. Response rates of more than 50% were reported with this combination by Preusser. Forty-one patients with metastatic or nonresectable gastric cancer received etoposide, 100 mg/m IV, day 4-6; adriamycin, 20 mg/m IV, days 1 and 7; cisplatin, 40 mg/m IV, days 2 and 8. Cycles were repeated every 4 weeks. Response rate, survival rate and toxicity were evaluat- ed. Results were as following: 1) The total 41 patients received EAP chemotherapy. Twenty-four patients were evaluated. The eighty eight cycles of chemotherapy were administered(mean, 3.7 cycles per patient, range, 2-8 cycles) 2) Of the sixteen patients with measurable disease, none had complete remission and 3(18.8%) achieved partial remission, resulting in an overall response rate of 18.8%. There were seven stable disease and six progressive disease. 3) The overall median survival was 25 weeks(7-68 wks) and the median time to progression was 16 weeks. 4) Main toxicities were leukopenia and thrombocytopenia. 16% of patients developed grade 3 to 4 myelosuppression and 4% developed severe infections. Nonhematologic toxicites such as nausea, vomiting and alopecia appear in all cases, but toxicities of WHO grade 4 were not observed. Neurologic toxicity and renal insufficiency WHO grade 1 were observed in 37% and l7 % of patients. In view of this low response rate, low survival rate and toxicity, this combination as a alliative therapy of advanced gastric cancer is not justified.
저 자   김준식(Joon Sik Kim),김정희(Jeong Hee Kim),어완규(Own Gyu Uh),김시영(Si Young Kim),윤휘중(Hwi Joong Yoon),조경삼(Kyung Sam Cho)